Fevipiprant
Chemical compound / From Wikipedia, the free encyclopedia
Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Unaffected by food[1] |
Metabolism | Hepatic glucuronidation |
Elimination half-life | ~20 hours |
Excretion | Renal (≤30%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.243.911 |
Chemical and physical data | |
Formula | C19H17F3N2O4S |
Molar mass | 426.41 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
By 2016 it had advanced to phase III[4] clinical trials for the treatment of asthma.[5] However, in 2019 Novartis announced that it was removing fevipiprant from its development program, given that the medicine has failed in two clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.[6]